Exemestane Plus Ovarian Function Suppression Is the Best Adjuvant Treatment of Premenopausal Women With Endocrine-Responsive Breast Cancer at Higher Risk of Relapse and With HER2-Negative Tumors.
作者信息
Conforti Fabio, Pala Laura
机构信息
Fabio Conforti, MD and Laura Pala, MD, European Institute of Oncology, IRCCS, Milan, Italy.
出版信息
J Clin Oncol. 2019 Jul 20;37(21):1838-1840. doi: 10.1200/JCO.19.00559. Epub 2019 Jun 7.
Abstract
摘要
相似文献
1
Exemestane Plus Ovarian Function Suppression Is the Best Adjuvant Treatment of Premenopausal Women With Endocrine-Responsive Breast Cancer at Higher Risk of Relapse and With HER2-Negative Tumors.依西美坦联合卵巢功能抑制是复发风险较高且肿瘤为HER2阴性的绝经前内分泌反应性乳腺癌女性的最佳辅助治疗方法。
J Clin Oncol. 2019 Jul 20;37(21):1838-1840. doi: 10.1200/JCO.19.00559. Epub 2019 Jun 7.
2
Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials.辅助内分泌治疗对激素受体阳性、人表皮生长因子受体2阴性的绝经前早期乳腺癌女性的绝对获益：TEXT和SOFT试验
J Clin Oncol. 2016 Jul 1;34(19):2221-31. doi: 10.1200/JCO.2015.64.3171. Epub 2016 Apr 4.
3
Adjuvant endocrine therapy for premenopausal women: Type and duration.绝经前女性的辅助内分泌治疗：类型和持续时间。
Breast. 2017 Aug;34 Suppl 1:S108-S111. doi: 10.1016/j.breast.2017.06.040. Epub 2017 Jun 29.
4
Adjuvant endocrine therapy for premenopausal women: risk stratification, type and duration.绝经前女性的辅助内分泌治疗：风险分层、类型和持续时间。
Breast. 2019 Nov;48 Suppl 1:S85-S88. doi: 10.1016/S0960-9776(19)31131-2.
5
Revisiting adjuvant ovarian suppression in premenopausal breast cancer patients.重新审视绝经前乳腺癌患者的辅助性卵巢抑制治疗。
Indian J Cancer. 2019 Oct-Dec;56(4):293-296. doi: 10.4103/ijc.IJC_697_18.
6
Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer.绝经前雌激素受体阳性早期乳腺癌患者内分泌治疗的挑战及应对
Drugs. 2015 Aug;75(12):1311-21. doi: 10.1007/s40265-015-0433-7.
7
Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials.国际乳腺癌研究组TEXT和SOFT辅助内分泌治疗试验中35岁以下女性的治疗疗效、依从性和生活质量
J Clin Oncol. 2017 Sep 20;35(27):3113-3122. doi: 10.1200/JCO.2016.72.0946. Epub 2017 Jun 27.
8
Triptorelin: A Review of its Use as an Adjuvant Anticancer Therapy in Early Breast Cancer.曲普瑞林：作为早期乳腺癌辅助抗癌疗法的应用评价。
Drugs. 2017 Dec;77(18):2037-2048. doi: 10.1007/s40265-017-0849-3.
9
Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?绝经前内分泌反应性早期乳腺癌：哪些人接受化疗？
Ann Oncol. 2008 Jul;19(7):1231-1241. doi: 10.1093/annonc/mdn037. Epub 2008 Mar 5.
10
Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.早期乳腺癌绝经前女性接受卵巢抑制时，辅助依西美坦与他莫昔芬的患者报告结局（TEXT和SOFT）：两项3期随机试验的联合分析
Lancet Oncol. 2015 Jul;16(7):848-58. doi: 10.1016/S1470-2045(15)00049-2. Epub 2015 Jun 16.
引用本文的文献
1
Adjuvant endocrine therapy for premenopausal women with breast cancer: Patient adherence and physician prescribing practices in Mexico.乳腺癌绝经前女性的辅助内分泌治疗：墨西哥的患者依从性和医生处方实践。
Breast. 2021 Oct;59:8-15. doi: 10.1016/j.breast.2021.05.013. Epub 2021 Jun 1.
本文引用的文献
1
Ovarian Suppression in Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.绝经前乳腺癌辅助内分泌治疗中的卵巢抑制
J Clin Oncol. 2019 Apr 10;37(11):858-861. doi: 10.1200/JCO.18.01360. Epub 2019 Feb 11.
2
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.绝经前乳腺癌的辅助内分泌治疗。
N Engl J Med. 2018 Jul 12;379(2):122-137. doi: 10.1056/NEJMoa1803164. Epub 2018 Jun 4.
3
Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials.绝经前内分泌反应型早期乳腺癌女性的辅助治疗：TEXT和SOFT试验设计
Breast. 2013 Dec;22(6):1094-100. doi: 10.1016/j.breast.2013.08.009. Epub 2013 Oct 2.
Zotero 插件